Italian Journal of Medicine, 2013 AIM OF THE STUDY To review the best evidence-based knowledge about the clinical pharmacology and use of fondaparinux. DESIGN OF THE STUDY Narrative review. RESULTS Fondaparinux is a synthetic pentasaccharide anticoagulant that binds selectively with high
G. Airoldi, M. Campanini
doaj +5 more sources
Associação entre o Uso de Fondaparinux com Acesso Radial e Desfechos Clínicos em Pacientes com Síndrome Coronariana Aguda sem Supradesnivelamento do Segmento ST [PDF]
Arquivos Brasileiros de CardiologiaResumo Fundamento: Tanto o fondaparinux quanto o acesso radial têm sido associados a menores taxas de eventos adversos cardiovasculares maiores (MACE) em pacientes com síndrome coronariana aguda (SCA).
Luiz Eduardo Fonteles Ritt +10 more
doaj +2 more sources
Fondaparinux Sodium: Recent Advances in the Management of Thrombosis
Journal of Cardiovascular Pharmacology and Therapeutics, 2023 Fondaparinux sodium is a chemically synthesized selective factor Xa inhibitor approved for the prevention and treatment of venous thromboembolic events, that is, deep vein thrombosis, pulmonary embolism, and superficial vein thrombosis, in acutely ill ...
Rupert M. Bauersachs MD
doaj +2 more sources
Fondaparinux monitoring in a patient with heparin-induced thrombocytopenia on hemodialysis [PDF]
Srpski Arhiv za Celokupno Lekarstvo, 2016 Introduction. Heparin-induced thrombocytopenia associated to hemodialysis is rare. In case when citrate dialysis and/or non-heparin anticoagulants are not available, only possible medication to use for anticoagulation during hemodialysis is ...
Kušić Jovana +6 more
doaj +2 more sources
Fondaparinux versus argatroban for the management of suspected or confirmed heparin-induced thrombocytopenia: a propensity score–matched cohort study [PDF]
Frontiers in MedicineBackgroundHeparin-induced thrombocytopenia (HIT) is a prothrombotic, immune-mediated adverse drug reaction associated with significant morbidity and mortality.
Lama Alfehaid +24 more
doaj +2 more sources
Clinical and Applied Thrombosis/Hemostasis, 2021 We analyzed data for women who received fondaparinux for ≥7 days during pregnancy. The study retrospectively included women who received fondaparinux pre-, peri- and/or postpartum for ≥7 days for prophylaxis/venous thromboembolism (VTE) treatment at ...
Jürgen Koscielny +2 more
exaly +2 more sources
Fondaparinux and acute coronary syndromes: update on the OASIS 5–6 studies
Vascular Health and Risk Management, 2010 François SchieleDepartment of Cardiology, University Hospital Jean-Minjoz, Besançon, FranceAbstract: Anticoagulant therapy is a major component in the management of acute coronary syndromes (ACS).
François Schiele
doaj +1 more source
Can this be considered a Fondaparinux-induced Thrombocytopenia? [PDF]
European Journal of Case Reports in Internal Medicine, 2014 We present a case of an old woman with previously documented heparin-induced thrombocytopenia (HIT), treated with fondaparinux, who presented with thrombocytopenia and venous thrombosis after exposure to a preventive dose of fondaparinux during ...
Barbara Mariotti +2 more
doaj +2 more sources
Evaluating the impact of continuous venovenous hemodiafiltration on the efficacy of prophylactic fondaparinux doses: a prospective single-center observational study [PDF]
Scientific ReportsCritically ill patients often need continuous renal replacement therapy (CRRT). This process can remove particles as large as 10 kDa, including medications such as fondaparinux.
Aleksander Aszkiełowicz +2 more
doaj +2 more sources
Fondaparinux in the management of patients with ST-elevation acute myocardial infarction
Vascular Health and Risk Management, 2006 Alexander GG TurpieHamilton Health Sciences Corporation – General Division, Hamilton, ON, CanadaAbstract: The death rate of patients with ST-segment elevation myocardial infarction (STEMI) remains substantial.
Alexander GG Turpie
doaj +1 more source